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Abstract 
Idiopathic orbital inflammatory disease (IOID) is an idiopathic inflammatory process within 
the orbit that can result in permanent visual impairment. Although high-dose oral cortico-
steroids are currently the mainstay of therapy, their long-term usage can cause significant 
toxicity. We present a case of IOID that was successfully treated with the anti-CD20 
monoclonal antibody rituximab following failed steroid sparing with conventional second-
line immunosuppressive agents.  © 2013 S. Karger AG, Basel 
Introduction 
Idiopathic orbital inflammatory disease (IOID) is an idiopathic inflammatory process 
within the orbit that can result in permanent visual impairment. Although high-dose oral 
corticosteroids are currently the mainstay of therapy, their long-term usage can cause 
significant toxicity [1]. We present a case of IOID that was successfully treated with the anti-
CD20 monoclonal antibody rituximab following failed steroid sparing with conventional 
second-line immunosuppressive agents. 
 Case Rep Ophthalmol 2013;4:216–218 
DOI: 10.1159/000356523 
 
© 2013 S. Karger AG, Basel 
www.karger.com/cop 
Shao et al.: Successful Corticosteroid-Sparing Effect of Rituximab in the Treatment of 
Refractory Idiopathic Orbital Inflammatory Disease 
 
 
217 
Case Report 
A 61-year-old woman presented with symptoms of left-sided headache, peri-orbital pain 
and left-sided ocular protrusion. Examination revealed a decrease in her visual acuity from 
6/6 to 6/24, which was associated with a left-sided relative afferent pupillary defect. Her left 
eye was proptotic by 3 mm on exophthalmometry, with associated ocular pain and 
conjunctival injection (fig. 1a). Extraocular movements were normal and intraocular 
examination proved unremarkable. 
Blood investigations including thyroid function tests, fasting blood glucose, liver and 
renal function tests, erythrocyte sedimentation rate and serum ACE were all normal, as was 
an immune screen including rheumatoid factor, antinuclear antibody and antineutrophil 
cytoplasm antibody. 
A provisional diagnosis of left IOID was made based on the clinical findings and negative 
blood investigations, and oral prednisolone was started at a dose of 60 mg/day. Her 
symptoms resolved rapidly and her vision and proptosis improved within days, supporting 
the diagnosis. However, she suffered a disease relapse when her prednisolone was tapered 
to 20 mg/day. Subsequent attempts at steroid sparing with mycophenolate mofetil 1 g b.i.d. 
and methotrexate 20 mg p.o. weekly proved ineffective over a period of 8 months. The 
patient started again at 60 mg/day prednisolone together with each second-line agent, but 
she was unable to get below 20 mg prednisolone without renewed disease activity. 
Measurement of IgG subclasses at this point demonstrated normal IgG4 levels, although this 
result may have been confounded by her concurrent treatment with corticosteroids and 
other immunosuppressive medication. 
She then received 2 infusions of rituximab 1 g i.v. separated by an interval of 2 weeks. 
This effected disease remission within 4 weeks and enabled her prednisolone to be tapered 
to 7.5 mg o.d. without relapse over a period of 2 months. Nine months on, she remains in 
remission on 7.5 mg prednisolone only and maintains a visual acuity of 6/6 with no relative 
afferent pupillary defect, and no abnormalities on repeat MR scanning (fig. 1b). 
Discussion 
Although the pathophysiology of IOID is poorly understood, raised IgG4 levels in serum 
samples and tissue biopsy of sufferers have implicated IgG4 in its aetiology, although the 
levels in this case were normal [2, 3]. Rituximab (a chimaeric monoclonal antibody against 
B-cell CD20) has been reported in the successful treatment of refractory orbital disease in 
granulomatosis with polyangiitis [3, 4] as well as in some cases of IOID [5–7]. Our case 
differs from previously reported cases in that our patient was sensitive to oral corticoster-
oids, but it proved impossible to effect steroid sparing with conventional second-line 
immunosuppressive agents, in contrast to rituximab. 
As IOID is rare and presents with heterogeneous clinical manifestations, prospective 
and randomised evidence investigating the role of rituximab in its treatment is unlikely to 
occur. Nevertheless, case reports including ours increasingly suggest that rituximab should 
be considered in refractory IOID unresponsive to conventional immunosuppression or in 
place of conventional immunosuppression in selected cases. 
 Case Rep Ophthalmol 2013;4:216–218 
DOI: 10.1159/000356523 
 
© 2013 S. Karger AG, Basel 
www.karger.com/cop 
Shao et al.: Successful Corticosteroid-Sparing Effect of Rituximab in the Treatment of 
Refractory Idiopathic Orbital Inflammatory Disease 
 
 
218 
Financial Support 
S.R.J.T. was supported by the UK National Institute of Health Research. The sponsor or 
funding organization had no role in the design or conduct of this research and the views and 
opinions expressed therein are those of the authors and do not necessarily reflect those of 
the UK Department of Health. The authors report no conflicts of interest. This study was 
approved by the Royal Surrey County Hospital R&D Department (12DEV0010). 
References 
1 Jacobs D, Galetta S: Diagnosis and management of orbital pseudotumor. Curr Opin Ophthalmol 
2002;13:347–351. 
2 Lindfield D, Attfield K, McElvanney A: Systemic immunoglobulin G4 (IgG4) disease and idiopathic orbital 
inflammation; removing ‘idiopathic’ from the nomenclature? Eye 2012;26:623–629. 
3 Joshi L, Salama AD, Pusey CD, Lightman S, Taylor SR: Rituximab in Wegener’s granulomatosis: PR3 titres 
predict relapse, but repeat treatment can be effective. Ophthalmology 2011;118:2498–2503. 
4 Taylor SR, Salama AD, Joshi L, Pusey CD, Lightman S: Rituximab is effective in the treatment of refractory 
ophthalmic Wegener’s granulomatosis. Arth Rheum 2009;60:1540–1547. 
5 Schafranski MD: Idiopathic orbital inflammatory disease successfully treated with rituximab. Clin 
Rheumatol 2009;28:225–226. 
6 Kurz PA, Suhler EB, Choi D, Rosenbaum JT: Rituximab for treatment of ocular inflammatory disease: a series 
of four cases. Br J Ophthalmol 2009;93:546–548. 
7 Wallace ZS, Khosroshahi A, Jakobiec FA, Deshpande V, Hatton MP, Ritter J, et al: IgG4-related systemic 
disease as a cause of ‘idiopathic’ orbital inflammation including orbital myositis, and trigeminal nerve 
involvement. Surv Ophthalmol 2012;57:26–33. 
 
 
 
Fig. 1. Transverse MR images of the brain and orbit (T1-weighted images), before (a) and after (b) the 
treatment with 2 doses of rituximab 1 g i.v. 
 
